Abstract Number: 2173 • 2017 ACR/ARHP Annual Meeting
Characteristics Unique to MDA5 and Anti-Ro/SSA-52 Kda Dual Antibody Positive Patients with Inflammatory Myopathies
Background/Purpose: The anti-melanoma differentiation-associated gene 5 antibody (MDA5) was recently classified as a myositis-specific antibody (MSA), and has been associated with rapidly progressive interstitial lung…Abstract Number: 98 • 2017 ACR/ARHP Annual Meeting
Impact of a Lung Ultrasound Course for Rheumatology Specialist (IMPACT-2)
Background/Purpose: Although much emphasis is focused on lung ultrasonography(US) within the critical care field, there is a growing interest in the use of lung…Abstract Number: 2392 • 2017 ACR/ARHP Annual Meeting
Impact of the Pattern of Interstitial Lung Disease on Mortality in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
ABSTRACT Impact of the Pattern of Interstitial Lung Disease on Mortality in Rheumatoid Arthritis: A systematic review and meta-analysis Background/Purpose: Interstitial lung disease affects 10-15%…Abstract Number: 257 • 2017 ACR/ARHP Annual Meeting
The Use of Positron Emission Tomography (PET)-Scan for the Quantitative Assessment of Interstitial Lung Disease in Systemic Sclerosis
Background/Purpose: Interstitial lung disease (ILD) in systemic sclerosis is treated by immunosuppressive drugs (e.g. cyclophosphamide), aimed at reduction of inflammatory response . Differentiation between inflamed…Abstract Number: 2402 • 2017 ACR/ARHP Annual Meeting
Rituximab in Rheumatoid Arthritis with Interstitial Lung Disease: A Multicenter Study of 32 Patients
Background/Purpose: Anti-TNFα drugs and several conventional disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate (MTX) have been involved in the development of Interstitial Lung Disease (ILD).…Abstract Number: 552 • 2017 ACR/ARHP Annual Meeting
Mast Cells Are Involved in the Pathogenesis of Sjögren Syndrome By Inducing Tissue Fibrosis
Background/Purpose: Mast cells have been implicated in many immune-inflammatory disorders. They mediate a variety of inflammatory and fibrotic conditions, but their role in sialadenitis and…Abstract Number: 2412 • 2017 ACR/ARHP Annual Meeting
Mortality and Clinical Features in Rheumatoid Arthritis and Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) is the most common extra-articular manifestation in Rheumatoid Arthritis (RA) generating higher mortality in these patients. The objective is to…Abstract Number: 749 • 2017 ACR/ARHP Annual Meeting
Treatment with Cyclophosphamide for Systemic Sclerosis-Interstitial Lung Disease Does Not Lead to a Sustained Improvement in Lung Function in Two Independent Cohorts
Background/Purpose: Compared with placebo, treatment with cyclophosphamide (CYC) improved lung function in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD) after 1 year in Scleroderma…Abstract Number: 2675 • 2017 ACR/ARHP Annual Meeting
Lung Transplant Trends in Patients’ with Systemic Sclerosis Using UNOS (United Network Organ Sharing) Database from 2000-2014
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disease once characterized by high mortality rates now with better outcomes. Pulmonary disease has overtaken renal failure…Abstract Number: 861 • 2017 ACR/ARHP Annual Meeting
CD11b+Gr1dim tolerogenic Dendritic Cell-like Cells Suppress the Progression of Interstitial Lung Disease in SKG Mice
CD11b+Gr1dim tolerogenic Dendritic Cell-like Cells Suppress the Progression of Interstitial Lung Disease in SKG Mice Background/Purpose: SKG mice develop interstitial lung disease (ILD) resembling rheumatoid arthritis-associated…Abstract Number: 943 • 2017 ACR/ARHP Annual Meeting
The Course of the Forced Vital Capacity during Treatment for Systemic Sclerosis-Related Interstitial Lung Disease Predicts Long-Term Survival in 2 Independent Cohorts
Background/Purpose: While prior observational studies have identified predictors of mortality in systemic sclerosis-interstitial lung disease (SSc-ILD), no studies have evaluated predictors of long-term mortality in…Abstract Number: 1333 • 2017 ACR/ARHP Annual Meeting
Mortality of Tumor Necrosis Factor Transgenic Arthritic Mice with Interstitial Lung Disease Occurs with Pulmonary Arteriole Thickening and Right Ventricular Hypertrophy but Is Not Associated with Inducible Nitric Oxide Synthase Dependent Inflammatory Cell Infiltration
Background/Purpose: Rheumatoid arthritis associated interstitial lung disease (RA-ILD) occurs in up to 15% of RA patients, whose median survival expectancy after diagnosis is only 2.6…Abstract Number: 1684 • 2017 ACR/ARHP Annual Meeting
Effectiveness and Safety of Tacrolimus Following Intravenous Cyclophosphamide Pulse Therapy As the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease
Background/Purpose: Systemic sclerosis (SSc) is the disease characterized by organ fibrosis with unknown etiology, and pulmonary involvement is one of major cause of death. However,…Abstract Number: 1695 • 2017 ACR/ARHP Annual Meeting
Baseline Characteristics and Outcomes in a Retrospective Cohort of Patients with Systemic Sclerosis Related Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) is a major contributor to morbidity and mortality in systemic sclerosis (SSc). We sought to identify the distribution of clinical…Abstract Number: 1702 • 2017 ACR/ARHP Annual Meeting
Disease Progression in Systemic Sclerosis Patients with Concomittant or Isolated Interstitial Lung Disease and Pulmonary Arterial Hypertension in the Scleroderma Cohort Singapore
Background/Purpose: Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are leading causes of mortality in patients with systemic sclerosis (SSc). We aimed to determine…
- « Previous Page
- 1
- …
- 32
- 33
- 34
- 35
- 36
- …
- 39
- Next Page »